BAT Korea Subsidiary Launches "Neo Fresco" E-Cigarette Stick in Mint

BAT by 2FIRSTS.ai

Jul.26.2024

BAT Korea Subsidiary Launches "Neo Fresco" E-Cigarette Stick in Mint

BAT's Korean subsidiary launches new e-cigarette "Neo Fresco" with mint packaging in convenience stores for 4,800 Korean won.

According to a report by M-I.KR on July 26th, British American Tobacco (BAT) announced that its South Korean subsidiary will be launching the "Glo Hyper" series of e-cigarette-specific cigarette sticks called "Neo Fresco." The packaging design of "Neo Fresco" features a mint color. This new product will be available for sale at convenience stores and tobacco retailers nationwide, priced at 4,800 Korean won ($3.47). With the launch of this new product, the Glo Hyper series' lineup of "Neo" cigarette sticks has now expanded to a total of 10 varieties.

References:

[1] BAT 글로, 하이퍼 시리즈 전용 스틱 ‘네오 프레스코’ 선봬

Also Read:

[1] BAT Mid-Year Financial Results: Operating Profit Plummets by 28.3%, £500 Million New Categories Target in Jeopardy

[2] BAT Korea and PMI Seek Expansion in South Korean E-cigarette Market

[3] BAT GloTM 2023 Art Contest: Online Consumer Voting for Winners

#Asia #Products #South Korea #Heated tobacco products

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Ukraine intensifies crackdown on illicit tobacco and alcohol markets

Ukraine’s State Tax Service (GNS) has carried out around 24,000 on-site inspections in the tobacco and alcohol sectors this year, imposing more than ₴795 million (US$194 million) in fines and revoking over 2,500 business licences.

Oct.17 by 2FIRSTS.ai

Altria’s Nicotine Pouch Rollout in the U.S.: On! PLUS May Launch on October 14, Not Yet FDA-Approved

Altria’s new nicotine pouch On! PLUS™ is slated to launch in the U.S. on October 14, debuting in North Carolina, Texas, and Florida. The product uses NICOSILK™ technology and will offer multiple nicotine strengths. FDA approval has not yet been granted, but Helix says it is proceeding in line with compliance requirements.

Oct.11 by 2FIRSTS.ai

ARAC to 2Firsts | FDA’s Nicotine Pouch Pilot: What Hasn’t Changed Matters Most

In a contribution to 2Firsts, U.S. regulatory consultancy ARAC analyzes the FDA’s nicotine pouch PMTA pilot, cautioning that core evidentiary standards remain unchanged. The firm warns against overinterpreting the pilot and urges companies to act now rather than wait for uncertain regulatory shifts.

Oct.21

JUUL wins approval after FDA reversal of Marketing Denial Order

JUUL's regulatory journey from Marketing Denial Order to approval showcases FDA's evolving approach to e-cigarette oversight.